Sanofi S.A. revealed on Friday its IFRS net sales in the fourth quarter of fiscal 2022 stood at €10.73 billion, increasing by 7.3% compared to the corresponding timeframe a year ago. Net income jumped 29.1% to €1.46 billion, while earnings per share came in at €1.16, surging 29% from the fourth trimester in 2021.
The pharmaceutical giant's full-year results also recorded strong numbers, with sales rising 14% to €42.9 billion, and net income clocking in €6.72 billion, an 8% increase. Earnings per share for 2022 also went up 8% to reach €5.37.
"We remain confident in our outstanding commercial capabilities, including the ambition to reach sales of 10 billion euros for Dupixent in 2023, enabling us to guide to low single-digit EPS growth for the year," the company CEO Paul Hudson remarked.